Inflammatory bowel diseases (IBD) are relapsing disorders of the gastrointestinal tract characterized by chronic inflammation of the intestinal mucosa and tissue damage. Current pharmacological approaches in IBD primarily focus on dampening the inflammatory immune response. However, IBD is often associated with deficient or pathological tissue repair such as ulcers or fistulas and intestinal fibrosis or strictures. Therefore, understanding the mechanisms that promote tissue repair and physiological regeneration of the intestine is of outstanding importance towards the development of improved therapies in IBD. Macrophages have a fundamental role in inflammation as well as in tissue repair. While classically activated macrophages (M1) predominate during inflammation, the resolution of inflammation and intestinal wound healing is dependent on the transition of macrophages into an alternative, tissue repair (M2) state. We propose that the Axl and Mer (AM) receptor tyrosine kinases coordinate the phasing out from the M1 with the induction of the M2 response. We propose to (i) identify the molecular mechanism by which AM RTK signaling induces M2-macrophage polarization, (ii) identify the intestinal macrophage population in which the AM RTK signaling pathway coordinates the M1 to M2 switch to limit inflammation and induce tissue repair in the gut, and (iii) validate the AM pathway as a novel target for the combinatorial suppression of inflammation and induction of tissue repair in mouse models of injury in the gut. Unraveling the mechanism by which the AM pathway shapes macrophage polarization, ensuring effective silencing of the inflammatory state, together with the induction o the tissue repair program and obtaining proof-of-concept for engaging the AM RTKs in mouse models of intestinal injury will (1) significantly advance our knowledge on mucosal homeostasis and (2) pave the way for translational studies towards new and improved treatments in IBD.

Public Health Relevance

Inflammatory bowel diseases (IBD) are relapsing disorders of the gastrointestinal tract characterized by chronic inflammation of the intestine and tissue damage. Complete remission requires both the cessation of the pathological inflammatory response as well as the active removal of dead cells and their physiological replacement by the same cell types in order to preserve organ function. Here we will investigate the role of a family of receptors, TAM receptor tyrosine kinases, in coordinating the suppression of inflammation and induction of tissue repair responses towards the development of improved treatments in IBD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI089824-06
Application #
8928540
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Rothermel, Annette L
Project Start
2010-09-01
Project End
2019-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
6
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Yale University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Del Carmen, Silvina; Hapak, Sophie M; Ghosh, Sourav et al. (2018) Coagulopathies and inflammatory diseases: '…glimpse of a Snark'. Curr Opin Immunol 55:44-53
Mulla, Melissa J; Weel, Ingrid C; Potter, Julie A et al. (2018) Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators. Arthritis Rheumatol 70:891-902
Hastings, Andrew K; Yockey, Laura J; Jagger, Brett W et al. (2017) TAM Receptors Are Not Required for Zika Virus Infection in Mice. Cell Rep 19:558-568
Spadaro, Olga; Camell, Christina D; Bosurgi, Lidia et al. (2017) IGF1 Shapes Macrophage Activation in Response to Immunometabolic Challenge. Cell Rep 19:225-234
Hughes, Lindsey D; Bosurgi, Lidia; Ghosh, Sourav et al. (2017) Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal. Front Immunol 8:1743
Akalu, Yemsratch T; Rothlin, Carla V; Ghosh, Sourav (2017) TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev 276:165-177
Gómez-Galván, J B; Borrego, S; Tovar, N et al. (2017) Nilotinib as a risk factor for ischaemic stroke: A series of three cases. Neurologia 32:411-413
Uribe, Diana J; Mandell, Edward K; Watson, Adam et al. (2017) The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. PLoS One 12:e0179979
Cross, Sarah N; Potter, Julie A; Aldo, Paulomi et al. (2017) Viral Infection Sensitizes Human Fetal Membranes to Bacterial Lipopolysaccharide by MERTK Inhibition and Inflammasome Activation. J Immunol 199:2885-2895
DeBerge, Matthew; Yeap, Xin Yi; Dehn, Shirley et al. (2017) MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury. Circ Res 121:930-940

Showing the most recent 10 out of 28 publications